Skip to main content
NCBI home page
Annals of The Royal College of Surgeons of England logoLink to Annals of The Royal College of Surgeons of England
. 1992 Jan;74(1):9–12.

CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.

D P O'Brien 1, P G Horgan 1, D B Gough 1, R Skehill 1, H Grimes 1, H F Given 1
PMCID: PMC2497470  PMID: 1736805

Abstract

Carcinoma of the breast is the most common malignancy in women and is frequently associated with metastatic bone disease and its associated osteolytic morbidity and mortality. Traditional radiological methods for mass screening bony secondaries are not cost-effective. We examined the value of the tumour marker 'CA15-3' as an alternative to conventional isotope bone scintigraphy. A total of 218 patients with breast cancer was evaluated over a 4-year period. Venous CA15-3 levels were obtained at 3-monthly intervals and bone scintigraphy annually or if the patient developed locomotor symptoms or exhibited elevated CA15-3 levels. Of these patients, 33 with metastatic breast carcinoma had an elevated tumour marker level at the time of diagnosis of their metastases; bone metastases alone = 15/17 (88%), soft tissue metastases alone = 2/6 (33%), simultaneous bony and soft tissue metastases = 7/10 (70%). The preponderance of an elevated CA15-3 in metastatic bone disease, be it in isolation or in combination with non-bone metastases, yields a sensitivity, specificity and positive predictive value of 81.5%, 66% and 92%, respectively. Although 22 of the 27 patients had an elevated CA15-3 at the time of diagnosis of their bone metastases, the remaining five patients (with tumour marker levels in the normal range) showed a similar, albeit a delayed, increase (median = 3 months). Thus, all metastatic bone disease patients demonstrated elevated marker levels. We recommend CA15-3 as a simple, reliable and inexpensive screening method for detecting bone metastases in the patient with breast carcinoma.

Full text

PDF
9

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bishop H. M., Blamey R. W., Morris A. H., Rose D. H., Preston B., Lane J., Doyle P. J. Bone scanning: its lack of value in the follow-up of patients with breast cancer. Br J Surg. 1979 Oct;66(10):752–754. doi: 10.1002/bjs.1800661020. [DOI] [PubMed] [Google Scholar]
  2. Campbell D. J., Banks A. J., Oates G. D. The value of preliminary bone scanning in staging and assessing the prognosis of breast cancer. Br J Surg. 1976 Oct;63(10):811–816. doi: 10.1002/bjs.1800631020. [DOI] [PubMed] [Google Scholar]
  3. Citrin D. L., Furnival C. M., Bessent R. G., Greig W. R., Bell G., Blumgart L. H. Radioactive technetium phosphate bone scanning in preoperative assessment and follow-up study of patients with primary cancer of the breast. Surg Gynecol Obstet. 1976 Sep;143(3):360–364. [PubMed] [Google Scholar]
  4. Coleman R. E., Rubens R. D., Fogelman I. Reappraisal of the baseline bone scan in breast cancer. J Nucl Med. 1988 Jun;29(6):1045–1049. [PubMed] [Google Scholar]
  5. Coleman R. E., Rubens R. D. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987 Jan;55(1):61–66. doi: 10.1038/bjc.1987.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davies C. J., Griffiths P. A., Preston B. J., Morris A. H., Elston C. W., Blamey R. W. Staging breast cancer: role of bone scanning. Br Med J. 1977 Sep 3;2(6087):603–605. doi: 10.1136/bmj.2.6087.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Forrest A. P., Cant E. L., Roberts M. M., Stewart H. J., Sumerling M. D., Donaldson A. A., Smith A. F., Shivas A. A. Is the investigation of patients with breast cancer for occult metastatic disease worth while? Br J Surg. 1979 Oct;66(10):749–751. doi: 10.1002/bjs.1800661019. [DOI] [PubMed] [Google Scholar]
  8. Fujino N., Haga Y., Sakamoto K., Egami H., Kimura M., Nishimura R., Akagi M. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen. Jpn J Clin Oncol. 1986 Dec;16(4):335–346. [PubMed] [Google Scholar]
  9. Gerber F. H., Goodreau J. J., Kirchner P. T., Fouty W. J. Efficacy of preoperative and postoperative bone scanning in the management of breast carcinoma. N Engl J Med. 1977 Aug 11;297(6):300–303. doi: 10.1056/NEJM197708112970603. [DOI] [PubMed] [Google Scholar]
  10. Hayes D. F., Zurawski V. R., Jr, Kufe D. W. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986 Oct;4(10):1542–1550. doi: 10.1200/JCO.1986.4.10.1542. [DOI] [PubMed] [Google Scholar]
  11. Kerin M. J., McAnena O. J., O'Malley V. P., Grimes H., Given H. F. CA15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Br J Surg. 1989 Aug;76(8):838–839. doi: 10.1002/bjs.1800760826. [DOI] [PubMed] [Google Scholar]
  12. McNeil B. J., Pace P. D., Gray E. B., Adelstein S. J., Wilson R. E. Preoperative and follow-up bone scans in patients with primary carcinoma of the breast. Surg Gynecol Obstet. 1978 Nov;147(5):745–748. [PubMed] [Google Scholar]
  13. Monypenny I. J., Grieve R. J., Howell A., Morrison J. M. The value of serial bone scanning in operable breast cancer. Br J Surg. 1984 Jun;71(6):466–468. doi: 10.1002/bjs.1800710622. [DOI] [PubMed] [Google Scholar]
  14. O'Dwyer P. J., Duffy M. J., O'Sullivan F., McDermott E., Losty P., O'Higgins N. J. CEA and CA 15-3 in primary and recurrent breast cancer. World J Surg. 1990 Sep-Oct;14(5):562–566. doi: 10.1007/BF01658788. [DOI] [PubMed] [Google Scholar]
  15. Perez D. J., Powles T. J., Milan J., Gazet J. C., Ford H. T., McCready V. R., MacDonald J. S., Coombes R. C. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 1983 Sep 10;2(8350):613–616. doi: 10.1016/s0140-6736(83)90692-x. [DOI] [PubMed] [Google Scholar]
  16. Spencer G. R., Khan M., Bird C., Seymour R., Brown T. R., Collins C. D. Is bone scanning of value in patients with breast cancer? Acta Chir Scand. 1981;147(4):247–248. [PubMed] [Google Scholar]
  17. Thompson R. J., Rubery E. D., Jones H. M. Radioimmunoassay of serum creatine kinase-BB as a tumour marker in breast cancer. Lancet. 1980 Sep 27;2(8196):673–675. doi: 10.1016/s0140-6736(80)92709-9. [DOI] [PubMed] [Google Scholar]
  18. Tormey D. C., Waalkes T. P. Clinical correlation between CEA and breast cancer. Cancer. 1978 Sep;42(3 Suppl):1507–1511. doi: 10.1002/1097-0142(197809)42:3+<1507::aid-cncr2820420823>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from Annals of The Royal College of Surgeons of England are provided here courtesy of The Royal College of Surgeons of England

RESOURCES